Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Beclometasone dipropionate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Clenil Modulite pressurised inhalation solution is used to help prevent the symptoms of mild, moderate or severe asthma. The active ingredient, beclometasone dipropionate, is one of a group of medicines called corticosteroids which are often referred to simply as steroids. Steroids have an anti-inflammatory action reducing the swelling and irritation in the walls of the small air passages in the lungs, and so ease breathing problems.
e Clenil Modulite Do not use Clenil Modulite:
Clenil Modulite Clenil Modulite is available in 4 different strengths. Your doctor will have decided which strength you need. Clenil Modulite 200 and Clenil Modulite 250 are not suitable for children. Always use your inhaler exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. Instructions for using your inhaler are given after the dosage section. It takes a few days for your inhaler to work. It is very important that you use it regularly. Do not stop treatment even if you feel better unless told to do so by your doctor. Do not stop using your inhaler abruptly. While you are using Clenil Modulite your doctor will want to check your asthma regularly by carrying out simple breathing tests and may need to carry out blood tests from time to time. Dosage: The starting dose will depend on how severe your asthma is and will be decided by your doctor. It may be higher than the doses given below. Your doctor will prescribe the lowest dose of Clenil Modulite that will control your symptoms. A device called a Volumatic spacer should always be used when:
200 micrograms (4 puffs) twice a day 100 micrograms (2 puffs) twice a day
Usually the most you would take in a day is: Adults and the elderly: Children:
800 micrograms (16 puffs) 400 micrograms (8 puffs)
The total daily dose may be divided into 2, 3 or 4 doses per day. Clenil Modulite 100 micrograms The common starting dose is: Adults and the elderly: Children:
200 micrograms (2 puffs) twice a day 100 micrograms (one puff) twice a day
Usually the most you would take in a day is: Adults and the elderly: Children:
800 micrograms (8 puffs) 400 micrograms (4 puffs)
The total daily dose may be divided into 2, 3 or 4 doses per day. Clenil Modulite 200 micrograms The common starting dose is: Adults and the elderly only:
200 micrograms (1 puff) twice a day
Usually the most you would take in a day is:
800 micrograms (4 puffs)
The total daily dose may be divided into 2, 3 or 4 doses per day. This product strength is not suitable for children Clenil Modulite 250 micrograms The common starting dose is: Adults and the elderly only:
500 micrograms (2 puffs) twice a day
Usually the most you would take in a day is:
2,000 micrograms (8 puffs)
The total daily dose may be divided into 2, 3 or 4 doses per day. This product strength is not suitable for children If you use more Clenil Modulite than you should: Tell your doctor as soon as possible. Your doctor may want to check the cortisol levels in your blood and therefore, may need to take a blood sample (cortisol is a steroid hormone which occurs naturally in the body). It is important that you take your dose as stated on the pharmacist's label or as advised by your doctor. You should not increase or decrease your dose without seeking medical advice. If you forget to use Clenil Modulite: If you forget to take your Clenil Modulite, miss out your forgotten dose and take the next dose when it is due. Do not take more puffs than you were told to take. Instructions for use: It is important that you know how to use your inhaler properly. Your doctor, nurse or pharmacist will show you how to use your inhaler correctly and will check regularly that you are using your inhaler correctly. You must follow their instructions carefully, so that you know how, when and how many puffs to inhale and how often you must use your inhaler. The instructions should be on the pharmacist's label and are given in this leaflet. If you are not sure what to do or have problems inhaling then ask your doctor, nurse or pharmacist for advice. This medicine is contained in a pressurised canister in a plastic casing with a mouthpiece. There is a dose indicator on the back of the inhaler which tells you how many puffs are left:
Each time you press the canister, the dose indicator rotates by a small amount. The number of puffs remaining is displayed in intervals of 20. Take care not to drop the inhaler as this may cause the dose indicator to count down.
1
2 1-2
3 3A
3B
7
4
5-6 4C 4B 4A 1. To remove the mouthpiece cover, hold between the thumb and forefinger, squeeze gently and pull apart as shown. Check inside and outside to make sure that the mouthpiece is clean, and that there are no foreign objects.
Testing Your Inhaler: If the inhaler is new or if it has not been used for three days or more, one puff should be released into the air to make sure that it works. If you are testing your inhaler for the first time, 200 should be displayed on the dose indicator. 2. Hold the inhaler upright as shown, with your thumb on the base, below the mouthpiece. Breathe out as far as is comfortable. 3. Place the mouthpiece in your mouth between your teeth and close your lips around it but do not bite it. 4. Just after starting to breathe in through your mouth press down on the top of the inhaler to release a puff while still breathing in steadily and deeply 5. Hold your breath; take the inhaler from your mouth and your finger from the top of the inhaler. Continue holding your breath for a few seconds or as long as is comfortable. Breathe out slowly. 6. If you are to take another puff, keep the inhaler upright and wait about half a minute before repeating steps 2 to 5. 7. After use always replace the mouthpiece cover to keep out dust and fluff. Replace firmly, snap into position and check the dose indicator. Important: Do not rush steps 2, 3, 4 and 5. It is important that you start to breathe in as slowly as possible just before operating the inhaler. Practice in front of a mirror for the first few times.
Please read back of this leaflet Chiesi item
PAG. 1/2
CHIESI FARMACEUTICI S.p.A. – Parma – Italy NOT TO TAMPER THIS DOCUMENT
Artwork Owner: MS – mail: [email protected] MATERIAL TIPE: DESCRIPTION OF MATERIAL: FORMAT: DIMENSIONS mm: FONT AND min. SIZE: LAETUS CODE:
MOCK-UP FOR SUBMISSION LEAFLET MOCK-UP CLENIL MOD. 50/100/200/250 mcg D.I. UK F091 BACK 180 x 800 AFTER FOLDING: 180 x 39 Arial 8,5 pt The laetus or datamatrix code assigned in the Datamatrix Laetus code production code will be used to avoid the mix-up code is dummy is dummy
or DATAMATRIX CODE:
Black + halft 20%
COLOUR PRINT N.: 1
DIECUT
Reason of the change: New mock-up for UK submission: EU F-gas Regulation_labeling requirements Text received on 15/11/2024 From: Darr K. CHECK BY
Name:
Date:
PROOF N. /
1 2
DATE
FROM: /CHANGE FOR
28/11/2024 START ACTIVITY 02/12/2024 Drawing change from 180 doses to 200 requested by Darr on 02/12/2024
When to replace your inhaler When the indicator shows 20 doses left, you should request a new inhaler from your doctor. This will ensure you have a replacement in good time. When the '0' appears centrally in the window the medicine has run out and you should discard the inhaler. Your inhaler may feel like there are still some contents remaining but any remaining puffs may not contain enough medicine and should not be used. If you see 'mist' coming from the top of the inhaler or the sides of your mouth, Clenil will not get into your lungs as it should. Take another puff, carefully following the instructions from Step 2 onwards. People with weak hands or children may find it easier to hold the inhaler with both hands. Put the two forefingers on top of the inhaler and both thumbs on the bottom below the mouthpiece. If you find it difficult to operate the inhaler while starting to breathe in you may use the Volumatic spacer device. Ask your doctor, pharmacist or a nurse about this device. However, the Volumatic spacer device must always be used if:
Like all medicines, Clenil Modulite can cause side effects, although not everybody gets them. If you notice an immediate increase in wheezing, shortness of breath and cough straight after using your inhaler, stop using Clenil Modulite and use a quick-acting 'reliever' inhaler immediately. Contact your doctor straightaway. Your doctor will review your asthma and may change your treatment and may prescribe a different inhaler to treat your asthma. The following side effects have been reported. Tell your doctor as soon as possible if you suffer from any of these side effects but do not stop treatment unless told to do so. Your doctor will try to prevent these effects by prescribing Clenil Modulite in the lowest dose possible to control your asthma. Very Common (may affect more than 1 in 10 people):
Clenil Modulite
What Clenil Modulite contains The active substance of your inhaler is beclometasone dipropionate. Each puff contains 50, 100, 200 or 250 micrograms of beclometasone dipropionate. The other ingredients are glycerol, ethanol and the propellant norflurane (HFC-134a). Clenil Modulite 50: This medicine contains fluorinated greenhouse gases. Each inhaler contains 12.130 g of norflurane (HFC-134a) corresponding to 0.017 tonne CO2 equivalent (global warming potential GWP = 1430). Clenil Modulite 100: This medicine contains fluorinated greenhouse gases. Each inhaler contains 12.130 g of norflurane (HFC-134a) corresponding to 0.017 tonne CO2 equivalent (global warming potential GWP = 1430). Clenil Modulite 200: This medicine contains fluorinated greenhouse gases. Each inhaler contains 11.950 g of norflurane (HFC-134a) corresponding to 0.017 tonne CO2 equivalent (global warming potential GWP = 1430). Clenil Modulite 250: This medicine contains fluorinated greenhouse gases. Each inhaler contains 11.780 g of norflurane (HFC-134a) corresponding to 0.017 tonne CO2 equivalent (global warming potential GWP = 1430). What Clenil Modulite looks like and content of the pack Clenil Modulite is a pressurised inhalation solution contained in an aluminum can with plastic actuator and protective cap. Each canister contains 200 puffs. Marketing Authorisation Holder and Manufacturer The Marketing Authorisation Holder of Clenil Modulite is Chiesi Limited, 333 Styal Road, Manchester, M22 5LG, United Kingdom. The manufacturer of Clenil Modulite is Chiesi Farmaceutici S.p.A., 96 via S. Leonardo, 43122 Parma, Italy or Chiesi S.A.S., 2 rue des Docteurs Alberto et Paolo Chiesi, 41260 La Chaussee Saint Victor, France.
Is this leaflet hard to see or read? Phone 0161 488 5555 for help. The leaflet was last revised in 12/2024 Volumatic is a registered trademark of the GlaxoSmithKline Group of Companies.
CP0016/15
Chiesi item
PAG. 2/2
Clenil Modulite 50 micrograms inhaler (with Dose Indicator) comes as inhaler containing 50mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Clenil Modulite 50 micrograms inhaler (with Dose Indicator) is beclometasone dipropionate.
Medicines with the same active substance, strength and form include: Clenil Modulite 50 micrograms inhaler (without Dose Indicator), Kelhale 50 micrograms per actuation pressurised inhalation solution, Soprobec 50 micrograms per actuation pressurised inhalation solution. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Clenil Modulite 50 micrograms inhaler (with Dose Indicator), as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Clenil Modulite is indicated for the prophylactic management of mild, moderate, or severe asthma in adults or children:
Mild asthma: Patients requiring intermittent symptomatic bronchodilator asthma medication on a regular basis
Moderate asthma: Patients with unstable or worsening asthma despite prophylactic therapy or bronchodilator alone
Severe asthma: Patients with severe chronic asthma and those who are dependent on systemic corticosteroids for adequate control of symptoms
Posology
Clenil Modulite is for inhalation use only. The Volumatic™ spacer device may be used by patients who have difficulty synchronising aerosol actuation with inspiration of breath.
The starting dose of inhaled beclometasone dipropionate should be adjusted to the severity of the disease. The dose may then be adjusted until control is achieved and then should be titrated to the lowest dose at which effective control of asthma is maintained.
Adults (including the elderly): The usual starting dose is 200 micrograms twice daily. In severe cases this may be increased to 600 to 800 micrograms daily. This may then be reduced when the patient's asthma has stabilised. The total daily dosage should be administered as two to four divided doses.
The Volumatic™ spacer device must always be used when Clenil Modulite is administered to adults and adolescents 16 years of age and older taking total daily doses of 1000 micrograms or greater.
Children: The usual starting dose is 100 micrograms twice daily. Depending on the severity of asthma, the daily dose may be increased up to 400 micrograms administered in two to four divided doses.
Clenil Modulite must always be used with the Volumatic™ spacer device when administered to children and adolescents 15 years of age and under, whatever dose has been prescribed.
Patients with hepatic or renal impairment: No dosage adjustment is needed in patients with hepatic or renal impairment.
Method of Administration
The aerosol spray is inhaled through the mouth into the lungs. The correct administration is essential for successful therapy. The patient must be instructed on how to use Clenil Modulite correctly and advised to read and follow the instructions printed on the Patient Information Leaflet carefully.
Instructions for Use
Patients should be instructed in the proper use of their inhaler (see patient information leaflet)
During inhalation, the patient should preferably sit or stand. The inhaler has been designed for use in a vertical position.
Testing the inhaler:
If the inhaler is new or has not been used for three days or more, one puff should be released into the air. It is not necessary to shake the inhaler before use because this is a solution aerosol.
Instruct the patient to remove the mouthpiece cover and check that it is clean and free from foreign objects. The patient should then be instructed to breathe out before placing the inhaler into their mouth. They should then close their lips around the mouthpiece and breathe in steadily and deeply. They must not bite the mouthpiece. After starting to breathe in through the mouth, the top of the inhaler should be pressed down. Whilst the patient is still breathing in, the patient should then remove the inhaler from their mouth and hold their breath for about 5 to 10 seconds, or as long as is comfortable, and then breathe out slowly. The patient must not breathe out into the inhaler. If another dose is required, the patient should be advised to wait 30 seconds before repeating the procedure just described. Finally, patients should breathe out slowly and replace the mouthpiece cover.
The patient should be told not to rush the procedure described. It is important that the patient breathes in as slowly as possible prior to actuation. Inform the patient that if a mist appears on inhalation, the procedure should be repeated.
There is a dose indicator on the back of the inhaler which tells you how many puffs are left, the dose indicator rotates by a small amount when a puff is delivered. The number of puffs remaining is displayed in intervals of 20.
Patients should consider getting a replacement when the indicator shows the number 20. The indicator will stop at 0 when all the recommended puffs have been used. Replace the inhaler when the indicator reads 0.
It may be helpful to advise children and patients with weak hands to hold the inhaler with two hands, by placing both forefingers on top of the inhaler and both thumbs at the bottom of the device.
Patients who find it difficult to co-ordinate actuation with inspiration of breath should be told to use a Volumatic™ spacer device to ensure proper administration of the product.
Young children may find it difficult to use the inhaler properly and will require help. Using the inhaler with the Volumatic™ spacer device with a face mask may help in children under 5 years.
Advise the patient to thoroughly rinse the mouth or gargle with water or brush the teeth immediately after using the inhaler.
The patient should be told of the importance of cleaning the inhaler at least weekly to prevent any blockage and to carefully follow the instructions on cleaning the inhaler printed on the Patient Information Leaflet. The inhaler must not be washed or put in water.
The patient should be told also to refer to the Patient Information Leaflet accompanying the VolumaticTM spacer device for the correct instructions on its use and cleaning.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Patients should be properly instructed on the use of the inhaler to ensure that the drug reaches the target areas within the lungs. Patients should also be informed that Clenil Modulite should be used on a regular basis, even when they are asymptomatic.
Clenil Modulite does not provide relief of acute asthma symptoms, which require a short-acting inhaled bronchodilator. Patients should have relief medication available.
Severe asthma requires regular medical assessment, including lung-function testing, as there is a risk of severe attacks and even death. Patients should be instructed to seek medical attention if short-acting relief bronchodilator treatment becomes less effective, or more inhalations than usual are required as this may indicate deterioration of asthma control. If this occurs, patients should be assessed and the need for increased anti-inflammatory therapy considered (eg. higher doses of inhaled corticosteroid or a course of oral corticosteroid).
Severe exacerbations of asthma must be treated in the usual way, i.e. by increasing the dose of inhaled beclometasone dipropionate, giving a systemic steroid if necessary, and/or an appropriate antibiotic if there is an infection, together with β-agonist therapy.
Treatment with Clenil Modulite should not be stopped abruptly.
Systemic effects of inhaled corticosteroids may occur, particularly when prescribed at high doses for prolonged periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). It is important that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control of asthma is maintained.
It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be reviewed with the aim of reducing the dose of inhaled corticosteroids, if possible, to the lowest dose at which effective control of asthma is maintained. In addition, consideration should also be given to referring the patient to a paediatric respiratory specialist.
Prolonged treatment with high doses of inhaled corticosteroids may result in clinically significant adrenal suppression.
Additional systemic corticosteroid cover should be considered during periods of stress or elective surgery.
The transfer to Clenil Modulite of patients who have been treated with systemic steroids for long periods of time or at high doses needs special care, since recovery from possible adrenocortical suppression may take considerable time. Reduction of the dose of systemic steroid can be commenced approximately one week after initiating treatment with Clenil Modulite. The size of the reduction should correspond to the maintenance dose of systemic steroid. For patients receiving maintenance doses of 10 mg daily or less of prednisolone (or equivalent) reductions in dose of not more than 1 mg are suitable. For higher maintenance doses, larger reductions in dose may be appropriate. These oral dosage reductions should be introduced at not less than weekly intervals.
Adrenocortical function should be monitored regularly as the dose of systemic steroid is gradually reduced.
Some patients feel unwell during withdrawal of systemic steroids despite maintenance or even improvement of respiratory function. They should be encouraged to persevere with inhaled beclometasone dipropionate and to continue withdrawal of systemic steroid, unless there are objective signs of adrenal insufficiency.
Patients weaned off oral steroids whose adrenocortical function is impaired should carry a steroid warning card indicating that they may need supplementary systemic steroids during periods of stress, eg. worsening asthma attacks, chest infections, major intercurrent illness, surgery, trauma, etc.
Replacement of systemic steroid treatment with inhaled therapy sometimes unmasks allergies such as allergic rhinitis or eczema previously controlled by the systemic drug. These allergies should be symptomatically treated with antihistamine and/or topical preparations, including topical steroids.
As with all inhaled corticosteroids, special care is necessary in patients with active or quiescent pulmonary tuberculosis.
Visual disturbance
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
Clenil Modulite contains a small amount of glycerol and ethanol (alcohol), approximately 9 mg per actuation, which is equivalent to 0.88 mg/kg per dose of eight actuations in adults and 1,54 mg/kg per dose of four actuations in children. The small amount of alcohol and glycerol in this medicine will not have any noticeable effects.
Clenil Modulite contains a small amount of ethanol. There is a theoretical potential for interaction in particularly sensitive patients taking disulfiram or metronidazole.
Beclometasone is less dependent on CYP3A metabolism than some other corticosteroids, and in general interactions are unlikely; however the possibility of systemic effects with concomitant use of strong CYP3A inhibitors (e.g. ritonavir, cobicistat) cannot be excluded, and therefore caution and appropriate monitoring is advised with the use of such agents.
There is no experience of the use of this product in pregnancy and lactation in humans. It should not be used in pregnancy or lactation unless the expected benefits to the mother are thought to outweigh any potential risks to the fetus or neonate.
There is inadequate evidence of safety of beclometasone dipropionate in human pregnancy. Administration of corticosteroids to pregnant animals can cause abnormalities of fetal development including cleft palate and intra-uterine growth retardation. There may therefore, be a risk of such effects in the human fetus. It should be noted, however, that the fetal changes in animals occur after relatively high systemic exposure. Beclometasone dipropionate is delivered directly to the lungs by the inhaled route and so avoids the high level of exposure that occurs when corticosteroids are given by systemic routes.
No specific studies examining the transfer of beclometasone dipropionate into the milk of lactating animals have been performed. It is reasonable to assume that beclometasone dipropionate is secreted in milk, but at the dosages used for direct inhalation there is low potential for significant levels in breast milk.
There is no experience with or evidence of safety of propellant HFA-134a in human pregnancy or lactation. However, studies of the effect of HFA-134a on reproductive function and embryofetal development in animals have revealed no clinically relevant adverse effects.
None reported
Adverse events are listed below by system class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1,000 and <1/100), rare (≥1/10,000 and <1/1,000), very rare (≤1/10,000), unknown (frequency cannot be estimated from the available data).
System organ Class
Adverse Reaction
Frequency
Infections and Infestations
Oral candidiasis (of the mouth and throat)
Very Common
Immune System Disorders
Hypersensitivity reaction with the following manifestations:
Rash, urticaria, pruritus, erythema
Uncommon
Oedema of the eyes, face, lips and throat
Very Rare
Endocrine Disorders
Adrenal suppression*, growth retardation* (in children and adolescents), bone density decreased*
Very Rare
Psychiatric Disorders (see section 4.4 Special warnings and precautions for use)
Psychomotor hyperactivity, sleep disorders, anxiety, depression, aggression, behavioural disorders (predominantly in children)
Unknown
Nervous System Disorders
Headache
Unknown
Eye Disorders
Cataract*, glaucoma*
Very Rare
Vision, blurred (see also section 4.4)
Unknown
Respiratory, Thoracic and Mediastinal Disorders
Hoarseness, throat irritation
Common
Paradoxial bronchospasm, wheezing, dyspnoea, cough
Very Rare
Gastrointestinal Disorders
Nausea
Unknown
*Systemic reactions are a possible response to inhaled corticosteroids, especially when a high dose is prescribed for a prolonged time (see section 4.4 Special warnings and precautions for use).
As with other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing, shortness of breath and cough after dosing. This should be treated immediately with a fast-acting inhaled bronchodilator. Clenil Modulite should be discontinued immediately, the patient assessed and, if necessary, alternative therapy instituted.
Candidiasis of the mouth and throat occurs in some patients, the incidence increasing with doses greater than 400 micrograms beclometasone dipropionate per day. Patients with high blood levels of Candida precipitins, indicating a previous infection, are most likely to develop this complication. Patients may find it helpful to rinse their mouth thoroughly with water after inhalation. Symptomatic oral candidiasis can be treated with topical antifungal therapy while continuing with Clenil Modulite.
Hoarseness or throat irritation may occur in some patients. These patients should be advised to rinse the mouth out with water immediately after inhalation. Use of the Volumatic™ spacer device may be considered.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Acute: Inhalation of doses in excess of those recommended may lead to temporary suppression of adrenal function. This does not require emergency action. In these patients treatment should be continued at a dose sufficient to control asthma; adrenal function recovers in a few days and can be verified by measuring plasma cortisol.
Chronic: Use of inhaled beclometasone dipropionate in daily doses in excess of 1,500 micrograms over prolonged periods may lead to adrenal suppression. Monitoring of adrenal reserve may be indicated. Treatment should be continued at a dose sufficient to control asthma.
Ask anything about Clenil Modulite 50 micrograms inhaler (with Dose Indicator). The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.